Relay Therapeutics (RLAY): Bellevue Group AG added to its stake +854K shares

8.23M

Shares reported · +854K vs prior quarter

0.63%

Disclosed portfolio weight

$28.5M

Reported value

Holdings as of

Jun 30, 2025

Filed

Aug 14, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jul 9, 2025Insider · 1 personInsiders: 2 sales (~$219K)
2. Jul 28, 2025Insider · 4 peopleInsiders: 4 sales (~$33K)
3. Jul 29, 2025Insider · 4 peopleInsiders: 4 sales (~$291K)

What came next

1. Nov 4, 2025Company filing · Form 8-K · Results, Executive changeChanged a top executive or board member, and reported its results (and 1 more item)“On November 4, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors (the "Board") of the Company increased the number of members of the Board from seven to nine and appointed each of Lonnel Coats and Habib Dable as members of the Board, effective as of November 4, 2025.”

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Relay Therapeutics

For Relay Therapeutics, OQRO holds 8 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its RLAY page.

How this filing works

• SEC Form 13F

Other disclosures at Relay Therapeutics

• SEC Form 4Oct 30, 2026
• SEC Form 4Oct 30, 2026
• SEC Form 4Oct 30, 2026
• SEC Form 4Oct 8, 2026
• SEC Form 4Oct 8, 2026
• SEC Form 4Oct 8, 2026

Everything OQRO holds on this company is on its RLAY page.